Overview

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia. Patients with solid tumors (including central nervous tumors) that are recurrent or refractory to standard therapy, or for whom standard therapy is not available. Once a maximum tolerated dose (MTD) has been established in patients with recurrent or refractory solid tumors, the tolerability of this dose will be tested in patients with refractory or recurrent leukemia and an expanded cohort of patients with refractory or recurrent solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

St. Jude Children's Research Hospital

Treatments:

Bevacizumab
Cyclophosphamide
Niacinamide
Sorafenib